Lack of interaction of buprenorphine with flunitrazepam metabolism

Objective: The authors' goal was to determine if the reported clinical adve rse interaction of flunitrazepam and buprenorphine was caused by inhibition of drug metabolism. Method: Inhibition of flunitrazepam metabolism by buprenorphine and norbupr enorphine were determined in three human liver microsome preparations carry ing the CYP2C19*1*/1 allele. Omeprazole metabolism mediated by CYP2C19 and CYP3A4 was used as a control reaction. Apparent K-i values were determined. Results: Norbuprenorphine did not inhibit the metabolism of flunitrazepam o r omeprazole. Buprenorphine inhibited the formation of CYP3A4-mediated path ways of 3-hydroxyflunitrazepam and omeprazole sulfone formation (K-i 118 an d 16 mu M) in human liver microsomes. Corresponding values were 38 and 90 m u M in cDNA-expressed CYP3A4 microsomes. Projected in vivo inhibition of CY P3A4-mediated metabolism of flunitrazepam by buprenorphine is 0.1%-2.5%. Es timated inhibition of buprenorphine N-dealkylation by flunitrazepam in vivo is 0.08%. Conclusions: The clinical interaction of flunitrazepam and buprenorphine is likely based on a pharmacodynamic mechanism.